X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs GLENMARK PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA GLENMARK PHARMA SUN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 15.3 13.9 110.6% View Chart
P/BV x 3.6 3.9 92.8% View Chart
Dividend Yield % 0.2 0.3 65.0%  

Financials

 SUN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
GLENMARK PHARMA
Mar-16
SUN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2011,262 95.1%   
Low Rs706672 105.2%   
Sales per share (Unadj.) Rs117.5270.6 43.4%  
Earnings per share (Unadj.) Rs19.624.9 78.8%  
Cash flow per share (Unadj.) Rs23.834.4 69.2%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.2 50.7%  
Book value per share (Unadj.) Rs130.5151.3 86.2%  
Shares outstanding (eoy) m2,406.60282.16 852.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.13.6 227.2%   
Avg P/E ratio x48.738.9 125.2%  
P/CF ratio (eoy) x40.128.1 142.6%  
Price / Book Value ratio x7.36.4 114.4%  
Dividend payout %5.18.0 63.5%   
Avg Mkt Cap Rs m2,294,813272,778 841.3%   
No. of employees `00014.710.0 147.1%   
Total wages/salary Rs m47,97113,782 348.1%   
Avg. sales/employee Rs Th19,169.87,614.9 251.7%   
Avg. wages/employee Rs Th3,253.01,374.8 236.6%   
Avg. net profit/employee Rs Th3,197.9700.2 456.7%   
INCOME DATA
Net Sales Rs m282,69776,340 370.3%  
Other income Rs m6,170356 1,732.0%   
Total revenues Rs m288,86776,696 376.6%   
Gross profit Rs m83,23914,172 587.4%  
Depreciation Rs m10,1352,691 376.6%   
Interest Rs m4,7691,789 266.6%   
Profit before tax Rs m74,50510,048 741.5%   
Minority Interest Rs m-11,1260-   
Prior Period Items Rs m-190-   
Extraordinary Inc (Exp) Rs m-6,8520-   
Tax Rs m9,3493,028 308.7%   
Profit after tax Rs m47,1597,019 671.9%  
Gross profit margin %29.418.6 158.6%  
Effective tax rate %12.530.1 41.6%   
Net profit margin %16.79.2 181.4%  
BALANCE SHEET DATA
Current assets Rs m308,64659,096 522.3%   
Current liabilities Rs m132,47740,018 331.0%   
Net working cap to sales %62.325.0 249.4%  
Current ratio x2.31.5 157.8%  
Inventory Days Days8375 110.6%  
Debtors Days Days88119 73.6%  
Net fixed assets Rs m133,60639,075 341.9%   
Share capital Rs m2,407282 852.8%   
"Free" reserves Rs m266,90930,281 881.4%   
Net worth Rs m314,04242,703 735.4%   
Long term debt Rs m31,16724,873 125.3%   
Total assets Rs m542,196111,026 488.3%  
Interest coverage x16.66.6 251.2%   
Debt to equity ratio x0.10.6 17.0%  
Sales to assets ratio x0.50.7 75.8%   
Return on assets %9.67.9 120.7%  
Return on equity %15.016.4 91.4%  
Return on capital %17.817.5 101.3%  
Exports to sales %14.043.3 32.3%   
Imports to sales %3.17.4 42.3%   
Exports (fob) Rs m39,57233,044 119.8%   
Imports (cif) Rs m8,8825,672 156.6%   
Fx inflow Rs m42,17136,945 114.1%   
Fx outflow Rs m21,58361,066 35.3%   
Net fx Rs m20,588-24,122 -85.4%   
CASH FLOW
From Operations Rs m67,6943,449 1,963.0%  
From Investments Rs m-44,549-8,802 506.1%  
From Financial Activity Rs m-19,2436,986 -275.5%  
Net Cashflow Rs m3,902934 417.8%  

Share Holding

Indian Promoters % 63.7 48.3 131.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 6.9 74.3%  
FIIs % 23.0 34.4 66.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.5 79.0%  
Shareholders   133,026 56,727 234.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PFIZER  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS